Acesso livre
Acesso livre

Vacinas

Opinião | Disponibilização das vacinas para outros países antes de fazer uma vacinação doméstica de reforço.

13 Ago, 2021 | 12:18h

Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA

Resposta de anticorpos à vacinação da COVID-19 em adultos com doença hematológica maligna.

13 Ago, 2021 | 12:17h

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

 

Comentário no Twitter

 

Estudo randomizado | Avaliação da vacina de mRNA da Moderna em adolescentes.

12 Ago, 2021 | 12:30h

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Comentários no Twitter

 

[Preprint] Efetividade das vacinas da Pfizer vs. Moderna contra a variante Delta da COVID-19 no Catar – A efetividade contra doença sintomática causada pela variante Delta foi de 53,5% para a vacina da Pfizer e de 84,8% para a da Moderna; a efetividade contra doença grave pela mesma variante foi de 89,7% para Pfizer e de 100% para a Moderna.

12 Ago, 2021 | 12:23h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Conteúdo relacionado: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Comentário no Twitter

 

Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.

12 Ago, 2021 | 12:21h

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Comentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Conteúdos relacionados:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Vacinação: Efetividade versus eficácia.

12 Ago, 2021 | 12:17h

Vaccination: Effectiveness versus Efficacy – by Luis Correa, MD

Vídeo | Perguntas frequentes sobre vacinação contra COVID-19 – Atualizações de agosto de 2021.

12 Ago, 2021 | 12:15h

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

Vacinas aplicadas nos últimos 20 anos podem evitar 50 milhões de mortes em países de baixa e média rendas.

12 Ago, 2021 | 12:00h

Vaccines given in last 20 years could prevent 50 million deaths in LMICs – Imperial College London

Estudo original: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world – eLife

Relatório CDC | Morbidade e mortalidade da COVID-19 ultrapassaram muito os potenciais riscos de efeitos colaterais causados pelas vacinas.

11 Ago, 2021 | 10:54h

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

Revisão | Características clínicas e tratamento farmacológico da trombocitopenia trombótica com trombose de seio venoso cerebral desencadeada por vacina contra COVID-19.

11 Ago, 2021 | 10:53h

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Conteúdos relacionados:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.